Haoxi Health Technology Limited Class A (HAO) AI Stock Analysis

• Market Cap: $22.28M
• Dividend Yield: N/A
• Average Volume (3M): 63.60K
• Price to Earnings (P/E): 4.2
• Beta (1Y): 1.32
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 30
• Sector: General
• Sector Strength: N/A
• Industry: Advertising Agencies
• EPS (TTM): 0.01
• Shares Outstanding: 2,131,595
• 10 Day Avg. Volume: 24,288
• 30 Day Avg. Volume: 63,600
• PEG Ratio: 14.72
• Price to Book (P/B): 2.69K
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.59K
• Enterprise Value/Market Cap: 188.88
• Enterprise Value/Revenue: 25.00
• Enterprise Value/Gross Profit: 2.07K
• Enterprise Value/Ebitda: 587.79
• 1Y Price Target: $1.00
• Price Target Upside: -24.81% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 61 Neutral
• Price Target: $1.50 ▲(12.78%Upside)

The overall score reflects strong financial performance due to significant revenue growth and a solid equity position, but is tempered by cash flow challenges and modest profit margins. The technical analysis indicates a mixed outlook, with price trends suggesting caution. The low P/E ratio enhances the valuation appeal, making it potentially attractive for value investors. Absence of earnings call data and corporate events limits further insights.

Haoxi Health Technology Limited Class A Business Overview & Revenue Model

Company Description

Haoxi Health Technology Limited Class A (HAO) is a company operating in the healthcare technology sector. It focuses on developing and providing innovative medical and wellness solutions that leverage advanced technologies to improve patient care and health outcomes. The company's core offerings include digital health platforms, telemedicine services, and wearable health monitoring devices, designed to enhance the accessibility and efficiency of healthcare delivery.

How the Company Makes Money

Haoxi Health Technology Limited generates revenue through multiple streams, primarily focusing on the sale and subscription of its digital health platforms and telemedicine services. The company offers subscription-based models for healthcare providers and patients to access its telemedicine platform, which facilitates virtual consultations and remote patient monitoring. Additionally, HAO earns revenue from the sale of its wearable health monitoring devices, which are marketed directly to consumers and through partnerships with healthcare institutions. Collaborations with insurance companies and healthcare providers also contribute to its earnings, enhancing the integration of its technology into existing healthcare systems.

Haoxi Health Technology Limited Class A Financial Statement Overview

Summary

Haoxi Health Technology Limited shows significant revenue growth and a turnaround in profitability, with a strong equity position and low leverage. However, challenges remain in cash flow generation and profit margins, indicating a need for improvement in financial efficiency and cash management.

Income Statement

Haoxi Health Technology Limited shows strong revenue growth with a substantial increase from $28.2M in 2023 to $48.5M in 2024, marking a growth rate of 71.88%. The gross profit margin in 2024 stands at 5.67%, indicating an improvement over previous years but still relatively low. The net profit margin for 2024 is 2.66%, demonstrating profitability but with room for improvement. EBIT and EBITDA margins are 3.54% and 3.68%, respectively, showing stability in earnings.

Balance Sheet

The company exhibits a solid equity position with a positive stockholders' equity of $11.27M in 2024, a significant turnaround from negative equity in earlier years. However, the debt-to-equity ratio is 0.11, indicating low leverage but also reflecting a cautious approach. The equity ratio is relatively strong at 72.69%, showcasing financial stability, though the overall asset base remains modest.

Cash Flow

Cash flow performance is mixed, with negative free cash flow of -$802,943 in 2024, although showing improvement from the previous year. The operating cash flow to net income ratio is -0.58, suggesting that operating activities are not yet fully supporting net income generation. Despite this, the company has improved its financing cash flow, indicating potential for future investments.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	48.97M	48.52M	28.23M	16.16M	12.85M
Gross Profit	2.03M	2.75M	2.06M	648.72K	605.58K
EBITDA	971.03K	1.79M	1.22M	271.77K	330.96K
Net Income	297.27K	1.29M	969.75K	244.59K	304.06K
Balance Sheet
Total Assets	22.07M	15.51M	4.46M	542.99K	2.81M
Cash, Cash Equivalents and Short-Term Investments	9.10M	6.66M	1.20M	293.51K	55.89K
Total Debt	1.23M	1.20M	897.61K	505.40K	1.15M
Total Liabilities	3.32M	4.23M	2.90M	2.01M	4.74M
Stockholders Equity	18.74M	11.27M	1.57M	-1.47M	-1.93M
Cash Flow
Free Cash Flow	-3.34M	-802.94K	-917.63K	―	2.65M
Operating Cash Flow	-3.30M	-747.58K	-872.13K	-675.36K	2.65M
Investing Cash Flow	-6.19M	-3.13M	-45.50K	―	―
Financing Cash Flow	16.83M	9.32M	1.80M	933.22K	-2.61M

Haoxi Health Technology Limited Class A Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.33
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAO, the sentiment is Positive. The current price of 1.33 is above the 20-day moving average (MA) of 1.29, below the 50-day MA of 1.37, and below the 200-day MA of 2.97, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.04 is Neutral, neither overbought nor oversold. The STOCH value of 51.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HAO.

Haoxi Health Technology Limited Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HAO	61 Neutral	$22.28M	4.16	2.92%	―	―	―
MCHX	61 Neutral	$90.25M	―	-16.55%	―	-2.67%	21.65%
INUV	59 Neutral	$71.82M	―	-34.39%	―	18.20%	50.08%
WIMI	58 Neutral	$32.90M	6.85	8.21%	―	-8.74%	―
Sector *	56 Neutral	$5.71B	21.48	-28.61%	5.64%	10.78%	-31.71%
FLNT	49 Neutral	$41.55M	―	-123.16%	―	-15.07%	33.40%
DRCT	47 Neutral	$11.48M	―	-320.07%	―	-69.54%	-19665.56%